CCP
REGN icon

Cassia Capital Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Cassia Capital Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-421
Closed -$300K – 59
2024
Q4 		$300K Sell
421
-330
-44% -$277K 0.19% 56
2024
Q3 		$789K Sell
751
-64
-8% -$71.2K 0.52% 30
2024
Q2 		$857K Buy
815
+38
+5% +$36.8K 0.56% 26
2024
Q1 		$748K Buy
777
+156
+25% +$148K 0.5% 33
2023
Q4 		$545K Buy
621
+32
+5% +$26.4K 0.45% 33
2023
Q3 		$485K Buy
589
+13
+2% +$10.2K 0.4% 31
2023
Q2 		$414K Buy
576
+204
+55% +$157K 0.33% 50
2023
Q1 		$306K Sell
372
-9
-2% -$6.79K 0.25% 45
2022
Q4 		$275K Buy
381
+2
+0.5% +$1.48K 0.23% 62
2022
Q3 		$261K Buy
379
+23
+6% +$14.5K 0.24% 36
2022
Q2 		$210K Hold
356
– – 0.21% 50
2022
Q1 		$249K Buy
356
+8
+2% +$5.06K 0.2% 49
2021
Q4 		$220K Buy
+348
New +$214K 0.15% 60

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Cassia Capital Partners's REGN Position: Q1 2025 in Review

Cassia Capital Partners sold out of Regeneron Pharmaceuticals (REGN) in Q1 2025, closing a stake of 421 shares — an estimated $300K sold.

Cassia Capital Partners first reported a position in REGN in Q4 2021 and held it in 13 quarters. The position peaked at $857K in Q2 2024. 1,291 funds tracked by Wall St. Rank hold REGN as of Q1 2025.

  • Cassia Capital Partners reported no remaining Regeneron Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Cassia Capital Partners sold 421 Regeneron Pharmaceuticals shares in Q1 2025, an estimated $300K.
  • Cassia Capital Partners first reported a position in Regeneron Pharmaceuticals in Q4 2021 and held it in 13 quarters.
  • Cassia Capital Partners's Regeneron Pharmaceuticals position peaked at $857K in Q2 2024.
  • 1,291 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2025.

Based on Cassia Capital Partners's 13F filing for Q1 2025, filed 22 Apr 2025.